The risk of cardiovascular morbidity and mortality is increased in rheumatoid arthritis. The classical cardiovascular risk factors, including smoking, hypertension, dyslipidaemia, insulin resistance and diabetes mellitus, obesity and physical inactivity do not appear to explain the excess cardiovascular risk in rheumatoid arthritis, although they do contribute, albeit in a different way or to a lesser extent, to rheumatoid arthritis in comparison with the general population. A very important link between rheumatoid arthritis and cardiovascular disease is inflammation as it plays a key role in all stages of atherosclerosis: from endothelial dysfunction to plaque rupture and thrombosis. It also has an influence on and accentuates some traditional cardiovascular risk factors, such as dyslipidaemia, obesity and insulin resistance. To date, the exact pathophysiologic mechanism by which this relation between cardiovascular disease and rheumatoid arthritis can be explained is not completely clear. Cardiovascular risk management in rheumatoid arthritis is mandatory. Unfortunately, the way this should be done remains a point of discussion. In this review issues regarding cardiovascular risk in rheumatoid arthritis and its management will be addressed, according to evidence presented in the latest studies and our own experience-based opinion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728982 | PMC |
| http://dx.doi.org/10.1177/1759720X13491025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Update on tocilizumab in rheumatoid arthritis: a narrative review.
Front Immunol
March 2025
Rheumatology Unit, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population. Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged as an effective treatment for RA. This narrative review provides an update on TCZ's efficacy and safety based on data from randomized controlled trials (RCTs) and real-world evidence (RWE).
View Article and Find Full Text PDFNavigating interstitial lung disease associated with rheumatoid arthritis (RA-ILD): from genetics to clinical landscape.
Front Med (Lausanne)
February 2025
Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects millions of people worldwide and is characterized by persistent inflammation, pain, and joint destruction. In RA, the dysregulation of the immune system is well documented. However, the genetic basis of the disease is not fully understood, especially when extra-articular organs are involved.
View Article and Find Full Text PDFBiomaterials for Modulating the Immune Microenvironment in Rheumatoid Arthritis.
BME Front
March 2025
MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China.
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by joint swelling and bone destruction. Despite an incomplete understanding of its genesis, RA is tightly linked to the intricate immunological milieu, involving disruptions in molecular signaling and an imbalance between the innate and adaptive immune systems. With advancements in biomaterials science, the role of biomaterials in RA treatment has evolved from mere drug delivery systems to therapeutic microenvironment modulators, providing drug-independent treatment strategies for RA.
View Article and Find Full Text PDFAssociation of oral opioid usage and mortality in patients with inflammatory arthritides: a Korean nationwide cohort study.
Rheumatology (Oxford)
March 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Objectives: Recent studies have raised concerns regarding usage of opioids, a class of drugs widely used for managing chronic pain in musculoskeletal disorders; however, its potential risks remain incompletely understood. This study aimed to evaluate the association between oral opioid use and mortality in a nationwide inflammatory arthritides (IA) cohort.
Methods: Data were obtained from the National Health Insurance Sharing Service database in South Korea, including 161 907 patients with seropositive rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis between 2010 and 2022.
[Research progress of JAK/STAT signaling pathway in rheumatoid arthritis pain].
Sheng Li Xue Bao
February 2025
Center for Translational Medicine Research on Sensory-Motor Diseases, Yan'an University, Yan'an 716000, China.
Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by synovitis and bone destruction. Its clinical characteristics are mainly joint pain, swelling, stiffness and joint deformity. Due to the poor efficacy of both drug and non-drug therapies, RA can significantly impact patients' quality of life and increase personal and socioeconomic burdens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!